SANA
Sana Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.85
−1.79%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -2.5%
- EBIT
- +19.5%
- EPS
- +28.3%
- Free cash flow
- +27.1%
- Operating cash flow
- +26.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +20.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- +7.2%
- EBIT
- +30.0%
- Net income
- +8.5%
- EPS
- +17.2%
- Free cash flow
- +43.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026